These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12611456)

  • 1. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
    Egawa C; Motomura K; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Inaji H; Koyama H; Noguchi S
    Breast Cancer Res Treat; 2003 Mar; 78(1):45-50. PubMed ID: 12611456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
    Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
    Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
    Takamura Y; Kobayashi H; Taguchi T; Motomura K; Inaji H; Noguchi S
    Int J Cancer; 2002 Mar; 98(3):450-5. PubMed ID: 11920599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
    Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
    Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    Pearson EJ; Nair A; Daoud Y; Blum JL
    Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
    Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
    Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
    Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
    Schouten PC; Gluz O; Harbeck N; Mohrmann S; Diallo-Danebrock R; Pelz E; Kruizinga J; Velds A; Nieuwland M; Kerkhoven RM; Liedtke C; Frick M; Kates R; Linn SC; Nitz U; Marme F
    Int J Cancer; 2016 Aug; 139(4):882-9. PubMed ID: 26946057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
    Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
    Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
    Söderlund K; Skoog L; Fornander T; Askmalm MS
    Radiother Oncol; 2007 Sep; 84(3):242-51. PubMed ID: 17707537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.